STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #645 by analyst upside · 2026-08-13
VIR
Vir Biotechnology, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+134.4%
implied upside to consensus target
Current Price $8.96
Consensus Target $21.0
Bull Target $30.0
Bear Target $15.0
Analysts Covering 9
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
6
Hold
0
Sell
0
52-Week Low $4.25
52-Week High $11.66
YTD Return +50.8%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.77
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $303M
Profit Margin -83.0%
52-WEEK RANGE
52-Week Low $4.25
52-Week High $11.66
Current Price $8.96
Bear Target $15.0
Bull Target $30.0
● Now $8.96 ● Target $21.0
TRADING DATA
Avg Volume 1.9M
YTD Return +50.8%
Analyst Count 9
Consensus Buy
Upside to Target +134.4%
Last Updated 2026-08-13

ANALYST SUMMARY

Vir Biotechnology, Inc. (VIR) is currently trading at $8.96 with a Wall Street consensus price target of $21.0, implying potential upside of 134.4% over the next 12 months. 9 analysts currently cover VIR, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $15.0.

VIR operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 50.8% year-to-date and is currently trading near the upper end of its 52-week range of $4.25 – $11.66.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for VIR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Morgan Stanley - Reiterated
Overweight → Overweight 2026-06-11 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-06-03 29% win rate (7 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-03-04 31% win rate (48 calls)
Barclays - Reiterated
Overweight → Overweight 2026-02-25 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-02-24 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-02-24 Building track record
Needham - Reiterated
Buy → Buy 2026-02-24 20% win rate (5 calls)
Needham reit
Buy → Buy 2026-02-09 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →